Status: current, Primitive. Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3660598019 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 3660599010 | Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 3660600013 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor (disorder) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 3660601012 | Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type II inhibitor | en | Synonym | Active | Initial character case insensitive | SNOMED CT core |
| 3660602017 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type II inhibitor | en | Synonym | Active | Initial character case insensitive | SNOMED CT core |
| 3660603010 | A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukaemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukaemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective haematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. | en | Definition | Active | Case sensitive | SNOMED CT core |
| 3660604016 | A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. | en | Definition | Active | Case sensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Disorder following clinical procedure | false | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of introduction procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Haematologic complication of procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Neoplastic complication of procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Sequela | false | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Therapy related acute myeloid leukaemia and myelodysplastic syndrome | true | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Associated morphology | Therapy-related acute myeloid leukaemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type | true | Inferred relationship | Some | 1 | |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Causative agent | Topoisomerase inhibitor | true | Inferred relationship | Some | 1 | |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of chemotherapy | true | Inferred relationship | Some | ||
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Following | Administration of antineoplastic agent | true | Inferred relationship | Some | 2 | |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Finding site | Bone marrow structure | true | Inferred relationship | Some | 1 | |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Due to | Administration of antineoplastic agent | true | Inferred relationship | Some | 3 | |
| Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of procedure | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Australian emergency department reference set
Clinical finding foundation reference set
Neoplasm and/or hamartoma reference set
Problem/Diagnosis reference set
Description inactivation indicator reference set
FHIR